What are the main alternatives to a CRO if you want to do more clinical work in-house?
Organizations typically choose between “buy execution” (a CRO) and “hire/keep capabilities internally” (in-house clinical development). If the goal is to replace or reduce CRO use, common alternatives are:
- Build an internal clinical development team. This usually includes clinical operations, trial management, site onboarding oversight, safety/drug safety support, monitoring strategy, data management oversight, and medical writing.
- Use vendors only for specific tasks. Instead of a full-service CRO, teams may contract selectively for monitoring, site activation, translation, imaging reads, pharmacovigilance activities, or data management, while keeping the overall trial management and strategy in-house.
- Use hybrid models (shared responsibility). Some companies keep protocol development, medical, safety strategy, and study oversight internally but outsource parts of execution through targeted vendor agreements.
These approaches can reduce dependence on a single CRO, but they shift staffing and program management burden toward the sponsor.
When do people choose CROs vs in-house development—and what drives “good” alternatives?
Sponsors tend to outsource when they need scale, speed to start, local site coverage, or specialized capabilities. Alternatives work best when you already have (or can build) the missing capability and when the trial mix is predictable enough to justify internal investment. Common drivers include:
- Trial frequency and portfolio stability (higher predictability makes in-house more feasible)
- Regulatory and therapeutic-area specialization (internal medical and safety expertise can be reused)
- Geographic spread and site network needs (CROs often provide this faster)
- Budget structure (in-house can look cheaper per program once fixed costs are absorbed, but carries higher upfront cost risk)
If you replace a CRO, what functions are best handled in-house vs outsourced?
A practical way to think about alternatives is by function. Many sponsors keep strategy and governance internal, while outsourcing execution components that are labor- or geography-intensive. Common patterns include:
- Kept in-house: protocol and study governance, investigator relationship strategy, overall project plan, safety oversight strategy, risk management decisions, and key medical writing.
- Often outsourced (targeted vendors): site monitoring at scale, central lab workflows, imaging vendor reading, eCOA/vendor services, translation, data entry/edits, or parts of pharmacovigilance operations.
The “good alternative” depends on your weakest link: if your biggest gap is site operations, a targeted vendor for site services may outperform building a full internal monitoring organization immediately.
What other service models compete with “CRO vs in-house”?
Beyond traditional CRO engagement, sponsors also use:
- “Functional service provider” (FSP) models: you contract specific clinical functions (e.g., monitoring, data management) rather than a whole program under one CRO umbrella.
- Clinical trial consulting and program management: external experts support trial design, feasibility, budgeting, vendor selection, and oversight, while operational execution remains primarily internal.
- Platform-based vendors: for certain workflow components (e.g., eTMF, trial supply chain coordination, central safety systems), you can reduce CRO involvement by adopting specialized infrastructure.
What should you evaluate when choosing an alternative (risk, quality, timelines, and compliance)?
If you’re replacing CRO coverage, you need controls that a CRO normally supplies. Key evaluation areas:
- Quality management: monitoring plans, audit readiness, deviations/CAPA processes, training records, and SOP alignment
- Data integrity and validation: how systems are configured, validated, and monitored
- Pharmacovigilance capability: case processing, timelines, quality audits, and safety signal escalation pathways
- Study start-up and site performance: how site identification/onboarding happens, and how start-up timelines are managed
- Resourcing flexibility: how you handle peaks (e.g., enrollment surges) without losing oversight
These factors determine whether the alternative truly reduces execution risk.
How do you handle start-up speed if you move away from CROs?
The main CRO advantage many sponsors cite is faster site activation and local coverage. To match that speed with alternatives, sponsors usually focus on:
- Pre-identified site networks and investigators
- Pre-built templates and contracts for site onboarding
- Clear escalation paths and decision timelines for protocol clarifications and amendment cycles
- A monitoring and training plan that scales quickly
Without these, internal teams often need time to ramp, which can negate the time advantage.
Are there patent or procurement implications when you switch models?
Execution model changes usually do not change patent strategy, but they can affect how you manage vendor data, documentation, and confidentiality. If your decision is tied to development timelines for market access, you can track sponsor-facing resources (including vendor and program-focused market intelligence) through sites such as DrugPatentWatch.com, which publishes drug development and IP-related updates that can matter for planning around exclusivity and timelines. [1]
What “good alternatives” look like in practice
Common “good” setups include:
- In-house clinical program management + functional vendors for execution-heavy tasks.
- Internal medical/safety leadership + external operations support for monitoring/site-related work.
- Hybrid models where you keep control of governance while outsourcing predictable workload spikes.
The best fit depends on whether you need capability you don’t have yet (in which case targeted vendors or consulting may be better) or you have a steady pipeline (in which case building internal depth can reduce long-term dependency).
---
Sources:
[1] https://www.drugpatentwatch.com/